Literature DB >> 27510002

Trends in Survival of Childhood Cancers in a University Hospital, Northeast Thailand, 19932012.

Phunnipit Wongmeerit1, Krittika Suwanrungruang, Arunee Jetsrisuparb, Patcharee Komvilaisak, Surapon Wiangnon.   

Abstract

BACKGROUND: In Thailand, a national treatment protocol for childhood leukemia and lymphoma (LL) was implemented in 2006. Access to treatment has also improved with the National Health Security system. Since these innovations, survival of childhood LL has not been fully described.
MATERIALS AND METHODS: Trends and survival of children under 15 with childhood cancers diagnosed between 1993 and 2012 were investigated using the hospitalbased data from the Khon Kaen Cancer Registry, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Thailand. Childhood cancers were classified into 12 diagnostic groups, according to the ICCC based on the histology of the cancer. Survival rates were described by period, depending on the treatment protocol. For leukemias and lymphomas, survival was assessed for 3 periods (199399, 20005, 200612) while for solid tumors it was for 2 periods (before and after 2000). The impacts of sex, age, use of the national protocol, and catchment area on leukemia and lymphoma were evaluated. Overall survival was calculated using the KaplanMeier method while the Cox proportional hazard model was used for multivariate analysis. Trends were calculated using the R program.
RESULTS: A total of 2,343 childhood cancer cases were included. Survival for acute lymphoblastic leukemia (ALL) from 19939, 20005, and 200612 improved significantly (43.7%, 64.6%, and 69.9%). This was to a lesser extent true for acute nonlymphoblastic leukemia (ANLL) (28.1%, 42.0%, and 42.2%). Survival of nonHodgkin lymphoma (NHL) also improved significantly (44%, 65.5%, and 86.8%) but not for Hodgkin disease (HD) (30.1%, 66.1%, and 70.6%). According to multivariate analysis, significant risk factors associated with poor survival in the ALL group were age under 1 and over 10 years, while not using the national protocol had hazard ratios (HR) of 1.6, 1.3, and 2.3 respectively. In NHL, only nonuse of national protocols was a risk factor (HR 3.9). In ANLL and HD, none of the factors influenced survival. Survival of solid tumors (liver tumors, retinoblastomas) were significantly increased compared to after and before 2000 while survival for CNS tumors, neuroblastoma and bone tumors was not changed.
CONCLUSIONS: The survival of childhood cancer in Thailand has markedly improved. Since implementation of national protocols, this is particularly the case for ALL and NHL. These results may be generalizable for the whole country.

Entities:  

Mesh:

Year:  2016        PMID: 27510002

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  4 in total

1.  Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand.

Authors:  Duangnate Rojanaporn; Taweevat Attaseth; Wimwipa Dieosuthichat; Kitikul Leelawongs; Samart Pakakasama; Usanarat Anurathapan; Ekachat Chanthanaphak; Sirintara Singhara Na Ayudhaya; Rangsima Aroonroch; Suradej Hongeng
Journal:  J Ophthalmol       Date:  2020-09-10       Impact factor: 1.909

2.  Increased Risk of Thai Childhood Acute Lymphoblastic Leukemia with the MiR196a2 T>C Polymorphism

Authors:  Sarinthorn Rakmanee; Samart Pakakasama; Suradej Hongeng; Sirima Sanguansin; Acharawan Thongmee; Wanida Pongstaporn
Journal:  Asian Pac J Cancer Prev       Date:  2017-04-01

3.  Survival Differences Between Males and Females Diagnosed With Childhood Cancer.

Authors:  Lindsay A Williams; Logan G Spector
Journal:  JNCI Cancer Spectr       Date:  2019-05-11

4.  Pediatric Solid Tumor Care and Multidisciplinary Tumor Boards in Low- and Middle-Income Countries in Southeast Asia.

Authors:  Mohd Yusran Othman; Sally Blair; Shireen A Nah; Hany Ariffin; Chatchawin Assanasen; Shui Yen Soh; Anette S Jacobsen; Catherine Lam; Amos H P Loh
Journal:  JCO Glob Oncol       Date:  2020-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.